Clinical Trials Sponsored by Biocair

Total 180 results

Biocad

Recruiting

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (DARVIVA)

Multiple Myeloma

Russian Federation
Biocad

Recruiting

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Hemophilia B

Russian Federation
Biocad

Recruiting

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

Melanoma (Skin) | Melanoma Stage III

Russian Federation, Belarus
Biocad

Recruiting

Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) (AQUARELLE)

Neuromyelitis Optica Spectrum Disorders

Russian Federation
Biocad

Recruiting

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis (MIRANTIBUS)

Multiple Sclerosis

Russian Federation
Biocad

Recruiting

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC (DOMAJOR)

Non-Squamous Non-Small Cell Neoplasm of Lung

Czechia, Romania, Georgia, Hungary, Russian Federation, Slovakia
Biocad

Completed

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

Healthy

Russian Federation
Biocad

Active, not recruiting

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (ELEFTA)

Axial Spondyloarthritis

Russian Federation
Biocad

Active, not recruiting

Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis (PATERA)

Psoriatic Arthritis

Russian Federation, Belarus
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Biocad

Completed

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Anemia

Russian Federation, Belarus
Biocad

Completed

Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

India, Russian Federation, Belarus
Biocad

Completed

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Hepatitis | Hepatitis C

Belarus, Russian Federation, India, Thailand
Biocad

Unknown

A Study of BCD-135 in Patients With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | NSCLC | Bladder Cancer

Russian Federation
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

Russian Federation
Biocad

Completed

First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects

Healthy
Biocad

Completed

Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

Russian Federation, Belarus
Biocad

Withdrawn

Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration (GALATIR)

Wet Age-related Macular Degeneration

Brazil, Russian Federation
BioGaia AB

Completed

Study Evaluating the Safety and Tolerability of a Probioitc

Healthy Volunteers | Tolerability | Safety

Sweden
Nobel Biocare

Completed

Study Assessing the Safety and Effectiveness of the Nobel Biocare N1 Concept System. (Evolution)

Dental Implant

Hungary, Italy, Netherlands
BioGaia AB

Completed

Study Evaluating the Safety and Tolerability

Healthy Volunteers

Sweden
Nobel Biocare

Completed

A 5 Year Clinical Study on NobelActive 3 mm Implants (NA 3 MM)

Single Tooth Implant
BioGaia AB

Completed

Double-blinded, Randomized, Placebo-controlled Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection

Recurrent Urinary Tract Infection in Adult Women

Sweden
AstraZeneca
Biocard

Completed

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Diabetes Mellitus, Type 2

Russian Federation
Nobel Biocare

Completed

A Study of Dental Implants Coated With Bone Morphogenetic Protein

Alveolar Ridge Abnormality

United States
Nobel Biocare

Terminated

All-On-4® Treatment Concept

Edentulous

Germany
Biocad

Recruiting

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

Axial Spondyloarthritis

Russian Federation, Belarus
Biocad

Recruiting

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Advanced Melanoma

Russian Federation, Belarus
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus
Biocad

Recruiting

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs (DEFENDOR)

Patients With Solid Tumours Who Receive Myelosupressive Therapy

Russian Federation
Biocad

Recruiting

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) (FERMATA)

Cervical Cancer

Georgia, Russian Federation, China, Turkey
Biocad

Completed

A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Healthy

Russian Federation
Biocad

Active, not recruiting

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma (FLAT)

Unresectable or Metastatic Melanoma

Russian Federation
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Active, not recruiting

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (OBERTON)

Melanoma | Melanoma Metastatic

Russian Federation, Belarus
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
Biocad

Completed

Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis (SOLAR)

Rheumatoid Arthritis

Russian Federation
Biocad

Completed

Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

Healthy

Russian Federation
Biocad

Completed

Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis
Biocad

Completed

International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Russian Federation
Biocad

Completed

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Russian Federation
Biocad

Completed

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Healthy

Russian Federation
Biocad

Completed

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Healthy Subjects

Russian Federation
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Biocad

Completed

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Melanoma

Russian Federation
Biocad

Completed

Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®

Leucocytosis
Biocad

Completed

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

Human Epithelial Receptor (HER)-2 Positive Breast Cancer

Ukraine, Russian Federation, Belarus, India
Biocad

Completed

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Hepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Coinfection

Russian Federation

3

Subscribe